Cempra Inc  

(Public, NASDAQ:CEMP)   Watch this stock  
Find more results for CEMP
17.97
+0.30 (1.70%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.51 - 18.18
52 week 14.03 - 45.75
Open 17.65
Vol / Avg. 599,193.00/678,955.00
Mkt cap 832.25M
P/E     -
Div/yield     -
EPS -2.10
Shares 48.20M
Beta 1.31
Inst. own 95%
Aug 1, 2016
Q2 2016 Cempra Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 1, 2016
Q2 2016 Cempra Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 23, 2016
Cempra Inc Analyst and Investor Day
Jun 9, 2016
Cempra Inc at Jefferies Healthcare Conference
May 26, 2016
Cempra Inc Announces Solithromycin Phase 2 CABP Topline Results in Japan - Webcast
May 20, 2016
Cempra Inc Annual Shareholders Meeting (Estimated)
May 18, 2016
Cempra Inc Annual Shareholders Meeting
May 2, 2016
Q1 2016 Cempra Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -1097.65% -333.64%
Operating margin -1088.99% -325.59%
EBITD margin - -325.34%
Return on average assets -60.32% -68.13%
Return on average equity -78.03% -101.98%
Employees 93 -
CDP Score - -

Address

6320 Quadrangle Dr Ste 360
CHAPEL HILL, NC 27517-7890
United States - Map
+1-919-5762306 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. Solithromycin has therapeutic potential and the spectrum of activity to target pathogenic bacteria. The Company also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).

Officers and directors

Garheng Kong M.D., Ph.D. Independent Chairman of the Board
Age: 40
Bio & Compensation  - Reuters
Prabhavathi B. Fernandes Ph.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Mark W. Hahn Chief Financial Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
David S. Moore Executive Vice President, Chief Commercial Officer
Age: 42
Bio & Compensation  - Reuters
David William Oldach Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Michael R. Dougherty Independent Director
Age: 57
Bio & Compensation  - Reuters
David N. Gill Independent Director
Age: 61
Bio & Compensation  - Reuters
Dov A. Goldstein M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
John H. Johnson Independent Director
Age: 57
Bio & Compensation  - Reuters
Richard S. Kent M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters